267413-07-0

Basic information

• Product Name: 2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE
• Synonyms: 2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE;1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile,2,3-dihydro-(9CI)
• CAS NO: 267413-07-0
• Molecular Formula: C₈H₇N₃
• Molecular Weight: 145.16
• Product Categories: PYRIDINE
• Mol File: 267413-07-0.mol

Chemical Properties

• Boiling Point: 303.1°C at 760 mmHg
• Flash Point: 137.1°C
• Appearance: /
• Density: 1.18g/cm³
• Vapor Pressure: 0.00095mmHg at 25°C
• Refractive Index: 1.615
• PKA: 4.16±0.20(Predicted)
• CAS DataBase Reference: 2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE(267413-07-0)
• EPA Substance Registry System: 2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBONITRILE(267413-07-0)

Safety Data

• Hazardous Substances Data: 267413-07-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2,3-Dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile is used as a chemical scaffold for pharmaceutical research, serving as a foundation for the development of new drug molecules. Its unique structure and potential biological activities make it a valuable compound in the search for novel therapeutic agents.
Used in Drug Development:
In the field of drug development, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile is utilized as a starting point for creating new pharmaceutical compounds. Its chemical properties and potential applications in medicine make it a promising candidate for further exploration and synthesis of potential drugs.

InChI:InChI=1/C9H8N2/c1-2-7-5-8-3-4-10-9(8)11-6-7/h1,5-6H,3-4H2,(H,10,11)

Upstream product

• 557-21-1 dicyanozinc 
• 115170-40-6 7-aza-5-bromoindoline 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 557-21-1 zinc(II) cyanide 
• 10592-27-5 7-azaindoline 

Downstream Products

• 556104-19-9 5-aminomethyl-7-azaindoline 
• 267876-17-5 N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ylmethyl)-2-(6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide 
• 849805-79-4 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 

Relevant articles and documents

Histone deacetylase inhibitors and its preparation method and use thereof

The invention discloses a histone deacetylase inhibitor and its preparation method and use, the invention discloses a compound of the formula I as shown, or its crystalline form, or its pharmaceutically acceptable salt, or solvate thereof, or prodrug thereof, or its metabolic product. The invention of the formula I illustrated new compound, has shown good deacetylase inhibition activity, with the histone deacetylase for clinical treatment of diseases associated with abnormal activity of a new pharmaceutical may be.

An expedient Pd/DBU mediated cyanation of aryl/heteroaryl bromides with K4[Fe(CN)6]

A practical Pd(PPh3)4/DBU catalytic system for the synthesis of pharmaceutically relevant aminopyridine nitrile intermediates, as well as a variety of other aryl nitriles using non-toxic K4[Fe(CN) 6] has been developed. The key features of our new protocol for cyanation lie in that the reaction can be carried out with readily available Pd(PPh3)4 under mild and green conditions, even without the assistance of other ligands. The Royal Society of Chemistry 2012.

NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND

Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X1 represents a group represented by the formula -C(=O)-NH- or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND

The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula -NH-C(=O)-, a group represented by the formula -C(=O)-NH-, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2or N; d is CY3or N; e is CY4or N; f is CY5or N; g is CY6or N; Y4, Y5, and Y6are independently hydrogen, C1-4alkyl, or halogen; Y1and Y2are independently hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, NH2, OH or C1-4alkoxy, and Y3is hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, —CN, NH2, OH or C1-4alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.

Azaindoles: Moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors

Starting from a 2-amino-6-methylpyridine P1 group and following a strategy of enlarging it whilst reducing its polarity, we have developed a series of potent, moderately basic azaindoles which are intrinsically much more selective for thrombin versus tryp

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is N Y 1 or O; c is CY 2 or N; d is CY 2; e is CY 1 or N; f is CY 1 or N; g is CY 1 or N; Y 1 is hydrogen, C 1-4 alkyl, or halogen; Y 2 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, halogen, NH 2, OH or C 1-4 alkoxy;A is and W, X, Z, R 3, R 4 and R 5 are defined in the specification.